Vinblastine

small molecule

Identifier: CI-DRUG-00000662
Entity page: /drug/vinblastine ↗
Edges: 249

Neighbours: 28 cancers15 genes10 trials6 approvals
Drawn: 59 of 59 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Vinblastine approved for …APPROVED_FOR10 of 6
→ approved for	Choriocarcinomahistology	supports	FDA ORIG	Choriocarcinoma	1	Regulatory	openfda	graph →
→ approved for	Kaposi Sarcomacancer	supports	FDA ORIG

→ approved for

FDA · US · 1987I. Frequently Responsive Malignancies • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Advanced carcinoma of the testis • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program - mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine - have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active.

FDA (US) · approved · 1987-04-29 · I. Frequently Responsive Malignancies • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma •…

—

approved

not mapped

Regulatory

openfda

open ↗

Vinblastine targets …TARGETS15 of 15
→ targets	TUBB6	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB2B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA3E	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB2A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1C	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB8	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB4A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB3	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA4A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA3C	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB4B	—	INHIBITOR	—	1	Curated	chembl	graph →

Vinblastine investigated for …INVESTIGATED_FOR15 of 24show all (up to 200)
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Hodgkin Lymphomahematologic_malignancy	unknown	4	Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	4	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Skin Neoplasmcancer_family	unknown	3	Skin Neoplasm	1	Curated	chembl	graph →
→ investigated for	Ovarian Neoplasmsubtype	unknown	3	Ovarian Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	3	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Urethra Neoplasmsubtype	unknown	3	Urethra Neoplasm	1	Curated	chembl	graph →
→ investigated for	Cervical Neoplasmsubtype	unknown	3	Cervical Neoplasm	1	Curated	chembl	graph →
→ investigated for	Bladder Neoplasmsubtype	unknown	3	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Testicular Neoplasmsubtype	unknown	3	Testicular Neoplasm	1	Curated	chembl	graph →
→ investigated for	Peripheral T-Cell Lymphoma, Not Otherwise Specifiedhematologic_malignancy	unknown	3	Peripheral T-Cell Lymphoma, Not Otherwise Specified	1	Curated	chembl	graph →
→ investigated for	Leukemiacancer_family	unknown	3	Leukemia	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	3	Melanoma	1	Curated	chembl	graph →
→ investigated for	Gliomasubtype	unknown	2	Glioma	1	Curated	chembl	graph →
→ investigated for	Paragangliomasubtype	unknown	2	Paraganglioma	1	Curated	chembl	graph →

Vinblastine investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 63show all (up to 200)
→ investigated in trials for	Lymphomacancer_family 30 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Hodgkin Lymphomahematologic_malignancy 27 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hodgkin Lymphoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasm 15 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Classic Hodgkin Lymphoma 14 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Classic Hodgkin Lymphoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Urethral Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Urethral Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Hodgkin Lymphoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Hodgkin Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Bladder Neoplasmsubtype 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Bladder Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Extragonadal Germ Cell Tumor 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Extragonadal Germ Cell Tumor	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Low Grade Glioma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Low Grade Glioma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Gliomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphocyte-Rich Classic Hodgkin Lymphoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphocyte-Rich Classic Hodgkin Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Testicular Germ Cell Tumor 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Testicular Germ Cell Tumor	2	Observed	clinicaltrials	graph →

Vinblastine studied in …STUDIED_INderived10 of 141show all (up to 200)
→ studied in	NCT04628767Phase 2/Phase 3 · recruiting Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer · 141 trials list this drug (29 active)	—	—	Renal Pelvis and Ureter Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05675410Phase 3 · recruiting A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab · 141 trials list this drug (29 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03585465Phase 1/Phase 2 · terminated Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors · 141 trials list this drug (29 active)	—	—	Childhood Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03233347Phase 2 · active not recruiting Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma · 141 trials list this drug (29 active)	—	—	Classic Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03407144Phase 2 · active not recruiting Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) · 141 trials list this drug (29 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03517137Phase 2 · active not recruiting Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study · 141 trials list this drug (29 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06745076Phase 2 · recruiting Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma · 141 trials list this drug (29 active)	—	—	Hodgkin Lymphoma,Classic Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07551583Phase 2 · recruiting Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL · 141 trials list this drug (29 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05180825Phase 2 · recruiting Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy · 141 trials list this drug (29 active)	—	—	Pleomorphic Xanthoastrocytoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05137262Phase 2 · active not recruiting A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder · 141 trials list this drug (29 active)	—	—	Urothelial Carcinoma,Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths